- Home
- TAC vs MRUS Comparison
TAC vs MRUS Comparison
Compare TAC & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TAC | MRUS |
|---|---|---|
| Founded | 1909 | 2003 |
| Country | Canada | Netherlands |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 5.1B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | TAC | MRUS |
|---|---|---|
| Price | $12.71 | $96.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 17 |
| Target Price | $21.63 | ★ $94.94 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 11-06-2025 | 10-31-2025 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,783,342,546.00 | $56,606,000.00 |
| Revenue This Year | N/A | $56.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 57.54 |
| 52 Week Low | $7.82 | $33.19 |
| 52 Week High | $17.88 | $97.14 |
Technical Indicators
Market Signals| Indicator | TAC | MRUS |
|---|---|---|
| Relative Strength Index (RSI) | 30.22 | 70.54 |
| Support Level | $12.34 | $96.78 |
| Resistance Level | $15.24 | $97.14 |
| Average True Range (ATR) | 0.52 | 0.17 |
| MACD | -0.11 | -0.12 |
| Stochastic Oscillator | 1.73 | 77.67 |
Price Performance
Historical ComparisonAbout TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.